13 results
8-K
EX-99.1
HLVX
HilleVax Inc
20 Mar 24
HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress
4:05pm
approximately 700 million cases of AGE and 200,000 deaths per year, resulting in direct and indirect healthcare system and societal costs of $10 billion
8-K
EX-99.1
HLVX
HilleVax Inc
9 Nov 23
HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm
in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older
8-K
EX-99.1
HLVX
HilleVax Inc
14 Aug 23
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
7:05am
billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children
8-K
EX-99.1
HLVX
HilleVax Inc
12 May 23
HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm
system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more
8-K
EX-99.1
14er6n y23u
10 Nov 22
HilleVax Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
4:15pm
8-K
EX-99.1
3f65g
10 Aug 22
HilleVax Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
4:20pm
424B4
zo0fijp lgqvdv4x4
29 Apr 22
Prospectus supplement with pricing info
4:02pm
S-1/A
tltx5j4
18 Apr 22
IPO registration (amended)
6:08am
S-1
aj6hu ptx756ay9h
6 Apr 22
IPO registration
4:21pm
DRS/A
jn3k8vkh
23 Nov 21
Draft registration statement (amended)
12:00am
DRS
65dvclq0j
19 Oct 21
Draft registration statement
12:00am
- Prev
- 1
- Next